MIROMATRIX MEDICAL INC (MIRO) Fundamental Analysis & Valuation
NASDAQ:MIRO • US60471P1084
Current stock price
3.39 USD
+0.02 (+0.59%)
At close:
3.39 USD
0 (0%)
After Hours:
This MIRO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MIRO Profitability Analysis
1.1 Basic Checks
- In the past year MIRO has reported negative net income.
- MIRO had a negative operating cash flow in the past year.
1.2 Ratios
- MIRO's Return On Assets of -117.04% is on the low side compared to the rest of the industry. MIRO is outperformed by 95.08% of its industry peers.
- The Return On Equity of MIRO (-176.38%) is worse than 88.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| ROIC | N/A |
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MIRO has a Gross Margin (47.92%) which is comparable to the rest of the industry.
- MIRO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MIRO Health Analysis
2.1 Basic Checks
- MIRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for MIRO has been increased compared to 1 year ago.
- The debt/assets ratio for MIRO has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -3.73, we must say that MIRO is in the distress zone and has some risk of bankruptcy.
- MIRO has a worse Altman-Z score (-3.73) than 88.52% of its industry peers.
- A Debt/Equity ratio of 0.03 indicates that MIRO is not too dependend on debt financing.
- MIRO has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: MIRO outperforms 59.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.73 |
ROIC/WACCN/A
WACC12.72%
2.3 Liquidity
- A Current Ratio of 3.46 indicates that MIRO has no problem at all paying its short term obligations.
- MIRO has a Current ratio (3.46) which is in line with its industry peers.
- MIRO has a Quick Ratio of 3.46. This indicates that MIRO is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.46, MIRO is in the better half of the industry, outperforming 62.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 |
3. MIRO Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 17.99% over the past year.
- Looking at the last year, MIRO shows a very strong growth in Revenue. The Revenue has grown by 3100.00%.
- MIRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 56.05% yearly.
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%
3.2 Future
- The Earnings Per Share is expected to grow by 19.77% on average over the next years. This is quite good.
- Based on estimates for the next years, MIRO will show a very strong growth in Revenue. The Revenue will grow by 490.87% on average per year.
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MIRO Valuation Analysis
4.1 Price/Earnings Ratio
- MIRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year MIRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.41%
EPS Next 3Y7.54%
5. MIRO Dividend Analysis
5.1 Amount
- No dividends for MIRO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIRO Fundamentals: All Metrics, Ratios and Statistics
3.39
+0.02 (+0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Industry Strength22.36
Industry Growth50.31
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)N/A N/A
Inst Owners22.32%
Inst Owner Change-7.87%
Ins Owners108.14%
Ins Owner Change0%
Market Cap92.95M
Revenue(TTM)960.00K
Net Income(TTM)-27.41M
Analysts80
Price Target3.19 (-5.9%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.41%
Min EPS beat(2)-12.04%
Max EPS beat(2)18.86%
EPS beat(4)2
Avg EPS beat(4)3.41%
Min EPS beat(4)-12.04%
Max EPS beat(4)18.86%
EPS beat(8)3
Avg EPS beat(8)-11.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)180.11%
Min Revenue beat(2)180.11%
Max Revenue beat(2)180.11%
Revenue beat(4)4
Avg Revenue beat(4)6622.69%
Min Revenue beat(4)180.11%
Max Revenue beat(4)25950.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)99900%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 96.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.98 | ||
| P/tB | 5.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.04
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.92% | ||
| FCFM | N/A |
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.83% | ||
| Cap/Sales | 23.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | -3.73 |
F-Score3
WACC12.72%
ROIC/WACCN/A
Cap/Depr(3y)718.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)3872.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%
EBIT growth 1Y0.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.34%
EBIT Next 3Y-21.4%
EBIT Next 5YN/A
FCF growth 1Y-135.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.27%
OCF growth 3YN/A
OCF growth 5YN/A
MIROMATRIX MEDICAL INC / MIRO Fundamental Analysis FAQ
What is the ChartMill fundamental rating of MIROMATRIX MEDICAL INC (MIRO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MIRO.
What is the valuation status of MIROMATRIX MEDICAL INC (MIRO) stock?
ChartMill assigns a valuation rating of 0 / 10 to MIROMATRIX MEDICAL INC (MIRO). This can be considered as Overvalued.
Can you provide the profitability details for MIROMATRIX MEDICAL INC?
MIROMATRIX MEDICAL INC (MIRO) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for MIRO stock?
The Earnings per Share (EPS) of MIROMATRIX MEDICAL INC (MIRO) is expected to grow by 32.47% in the next year.